A5015457609- Lymphoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Chemotherapy-induced organ toxicity mitigation
- Long-Term Effects of COVID-19
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- CAR-T cell therapy research
- Transport and Economic Policies
- Respiratory and Cough-Related Research
- Meningioma and schwannoma management
- Cardiac electrophysiology and arrhythmias
- Maritime Ports and Logistics
- Law, logistics, and international trade
- Multiple Myeloma Research and Treatments
- Cardiac Arrhythmias and Treatments
- Esophageal Cancer Research and Treatment
- Management of metastatic bone disease
- COVID-19 Clinical Research Studies
Stanford University
2022
Rutgers, The State University of New Jersey
2017-2018
Rutgers New Jersey Medical School
2017-2018
Hackensack University Medical Center
2018
Allama Iqbal Medical College
2014
Jinnah Postgraduate Medical Center
2014
Abstract Background Although classical Hodgkin lymphoma (cHL) is highly curable, 20%–30% of patients will not be cured with conventional treatments. The programmed death-1 (PD-1) inhibitors (PD-1i) nivolumab and pembrolizumab have been Food Drug Administration-approved for relapsed/refractory (R/R) cHL. There limited data on the real-world experience PD-1i in cHL it unknown whether fewer selected treated derive benefits similar to those observed published trials. Materials Methods We...